Quantification of the HPV-Attributable Cancer Mortality in Greece: Years of Life Lost and Productivity Costs
Author(s)
Ilias Gountas1, ANASTASIOS SKROUMPELOS, PhD2, Georgios Trimis, PhD3, Ugne Sabale, PhD4, Antonis Karokis, PhD3.
1Market access manager, MSD, Alimos, Greece, 2MSD, Athens, Greece, 3MSD, Alimos, Greece, 4Merck Sharp & Dohme International Service B.V., Vilnius, Lithuania.
1Market access manager, MSD, Alimos, Greece, 2MSD, Athens, Greece, 3MSD, Alimos, Greece, 4Merck Sharp & Dohme International Service B.V., Vilnius, Lithuania.
OBJECTIVES: Human papillomavirus (HPV) is a common cause of several cancer types, including head and neck, cervical, vulval, vaginal, anal, and penile cancers. The availability of HPV vaccines offers the potential for the prevention of HPV-related disease burden and its associated costs. The aim of the analysis is to quantify the impact of premature mortality due to HPV-related cancers on societal costs in Greece.
METHODS: The model considered cancer patients who died from 11 HPV-related cancers (oropharynx, oral cavity, nasopharynx, hypopharynx, pharynx, anal, larynx, vulval, vaginal, cervical, and penile) in 2019. The number of HPV-related deaths, years of life lost (YLL) and years of productive life lost (YPLL) were estimated based on published HPV-attributable fractions (Hartwig et al. Infect Agent Cancer 2017). YLL was adjusted with labor force participation, retirement age and multiplied by mean annual earnings, discounted at a 3% annual rate to calculate the present value of future lost productivity (PVFLP).
RESULTS: In 2022, 443 deaths attributable to HPV cancers were observed resulting in 6,388 YLL. Cervical cancer had the largest mortality burden, accounting for 60.5% of deaths, and 71.0% of the HPV-related YLL. The mean number of years of life lost due to deaths attributable to HPV-related cancers was 14.4 years, with 28.4% of those years representing productive life lost. The estimated YPLL and PVFLP associated with HPV-related premature mortality were 1,813 and €24.6M, respectively. Mean PVFLP per death was estimated at €55,674, with the highest PVFLP per death to be calculated for cervical cancer (€68,123).
CONCLUSIONS: There is a high disease burden of HPV-related cancer-related deaths in Greece, with a large economic impact to society due to substantial productivity losses. It is critical to implement targeted health interventions with the aim to reduce the incidence of HPV-related diseases, and the subsequent premature cancer deaths.
METHODS: The model considered cancer patients who died from 11 HPV-related cancers (oropharynx, oral cavity, nasopharynx, hypopharynx, pharynx, anal, larynx, vulval, vaginal, cervical, and penile) in 2019. The number of HPV-related deaths, years of life lost (YLL) and years of productive life lost (YPLL) were estimated based on published HPV-attributable fractions (Hartwig et al. Infect Agent Cancer 2017). YLL was adjusted with labor force participation, retirement age and multiplied by mean annual earnings, discounted at a 3% annual rate to calculate the present value of future lost productivity (PVFLP).
RESULTS: In 2022, 443 deaths attributable to HPV cancers were observed resulting in 6,388 YLL. Cervical cancer had the largest mortality burden, accounting for 60.5% of deaths, and 71.0% of the HPV-related YLL. The mean number of years of life lost due to deaths attributable to HPV-related cancers was 14.4 years, with 28.4% of those years representing productive life lost. The estimated YPLL and PVFLP associated with HPV-related premature mortality were 1,813 and €24.6M, respectively. Mean PVFLP per death was estimated at €55,674, with the highest PVFLP per death to be calculated for cervical cancer (€68,123).
CONCLUSIONS: There is a high disease burden of HPV-related cancer-related deaths in Greece, with a large economic impact to society due to substantial productivity losses. It is critical to implement targeted health interventions with the aim to reduce the incidence of HPV-related diseases, and the subsequent premature cancer deaths.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH201
Topic
Clinical Outcomes, Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Public Health
Disease
Oncology, Pediatrics, Vaccines